GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer
Karantanos T, Thompson TC.Cancer Cell. 2013 Jul 8;24(1):11-3. doi: 10.1016/j.ccr.2013.06.007.

Source

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Abstract

Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.